HIRONC

HIRONIC Co., Ltd. (CEO: Jinwoo Lee), a global manufacturer and supplier of aesthetic medical devices, announced that its HIFU-based lifting system, NEW DOUBLO 2.0 (known domestically as V-RO Advance), has obtained official import approvals from key regulatory authorities in the Middle East, including the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates, the Ministry of Public Health (MOPH) of Qatar, and the Saudi Food and Drug Authority (SFDA).

NEW DOUBLO 2.0 is the latest model in HIRONIC’s flagship DOUBLO HIFU series, incorporating advanced focusing technology and precise energy control algorithms to deliver stable and consistent treatment outcomes. The platform supports a versatile configuration of treatment handpieces, including HIFU, RF microneedling (RM), and RF, enabling physicians to address a wide range of clinical needs such as skin lifting, elasticity improvement, pore refinement, and skin tone enhancement. As a result, demand for the system continues to grow rapidly across global markets.

In recent months, HIRONIC has conducted on-site clinical training and operational education programs for NEW DOUBLO 2.0 in both the UAE and Saudi Arabia. These programs provided local medical professionals with comprehensive instruction, ranging from in-depth explanations of core technologies to hands-on training sessions, and received strong interest and positive feedback from clinics and practitioners in the region.

Following the latest import approvals, HIRONIC plans to further expand collaboration with regional partners while strengthening communication and engagement with the Middle Eastern market.

“Demand for premium aesthetic treatments is growing rapidly across the Middle East,” said a representative from HIRONIC. “With consecutive import approvals in the UAE, Saudi Arabia, and Qatar, we aim to actively highlight the technological competitiveness of NEW DOUBLO 2.0 and further solidify our brand presence in the region.”

Meanwhile, HIRONIC continues to expand global regulatory approvals for NEW DOUBLO 2.0, including ongoing processes in the United States (FDA) and Indonesia (KEMENKES RI), as part of its broader strategy to strengthen its global footprint.